Regulatory B cells promote the immunosuppressive microenvironment and progression of clear cell renal cell carcinoma [0.03%]
调节性B细胞促进透明细胞肾细胞癌免疫抑制微环境和肿瘤进展
Qintao Ge,Siqi Zhou,Jiahe Lu et al.
Qintao Ge et al.
Background: Regulatory B cells (Bregs) are critical mediators of immune modulation and tumor progression. However, their prognostic relevance and mechanistic roles in clear cell renal cell carcinoma (ccRCC) remain insuffi...
GLUT5 armouring enhances adoptive T-cell therapy anti-tumour activity under glucose-limiting conditions [0.03%]
GLUT5包被增强适应性T细胞疗法在血糖限制条件下的抗肿瘤活性
Robert Page,Olivier Martinez,Daniel Larcombe-Young et al.
Robert Page et al.
Background: Cancer immunotherapy with engineered T cells has become a standard treatment for certain haematological cancers. However, clinical trial outcomes for solid tumours are significantly lagging. A primary challeng...
High level of anti-drug antibodies is associated with shorter survival in advanced solid cancer patients treated with Immune checkpoint inhibitors [0.03%]
高水平的抗药抗体与接受免疫检查点抑制剂治疗的晚期实体瘤患者的生存期缩短有关
Rui Zhao,Weihao Wang,Jingliang Wang et al.
Rui Zhao et al.
Background: Camrelizumab has become the first-line treatment for most patients with advanced tumors. Among advanced tumor patients undergoing camrelizumab, the majority develop immunogenicity, resulting in the production ...
Heterogeneity of regulatory B cells in autoimmune diseases: implications for immune equilibrium and therapeutic strategies [0.03%]
自身免疫性疾病中调控性B细胞的异质性：对免疫平衡及治疗策略的意义
Haozhen Yan,Jing He,Xiang Lin
Haozhen Yan
Regulatory B cells (Bregs) play a crucial role in maintaining immune tolerance and preventing autoimmune diseases. However, in autoimmune conditions, the quantity and function of Bregs are often impaired, leading to pro-inflammatory microen...
Cancer vaccine trial evaluations: immunobridging and potential immunological endpoints [0.03%]
癌症疫苗试验评估：免疫衔接和潜在的免疫学终点指标研究
Ahmed Hussain,Benjamin Moxley-Wyles,Michael Bryan et al.
Ahmed Hussain et al.
Therapeutic cancer vaccines are an emerging class of immunotherapy, but challenges remain in effectively adapting approved vaccines to a growing number of adjuvants, combination therapies, and antigen-selection methods. Phase III clinical t...
Insights from the bottom-up development of LGR5-targeting immunotherapeutics [0.03%]
基于自下而上策略开发LGR5靶向免疫治疗的见解
Nico Mueller,Marc Andrew de la Roche,Maike de la Roche
Nico Mueller
Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a transcriptional target gene of the Wnt signalling pathway, is overexpressed in multiple cancers, including colorectal cancer (CRC), hepatocellular carcinoma (HCC) and pre...
Rosa Gomes Alves Martins,Mehmet M Tekin,Mark S Cragg et al.
Rosa Gomes Alves Martins et al.
Tumour-associated macrophages (TAM) are present in the majority of tumours, where they comprise one of the most abundant cell types, influencing tumour progression, metastasis, therapy resistance, and relapse. Hence, there is a great intere...
Intra-tumoural RAMP1+ B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma [0.03%]
肿瘤内RAMP1+B细胞促进食管鳞状细胞癌对新辅助抗PD-1治疗的耐药性
Hongyu Zhang,Yuchen Zhang,Pingjing Zhou et al.
Hongyu Zhang et al.
Introduction: The application of neoadjuvant immunotherapy in oesophageal squamous cell carcinoma (ESCC) reactivates anti-tumour immune responses and prolong postoperative survival. However, due to the heterogeneity of tu...
Implementing adjuvant immunotherapy following radical chemoradiotherapy for stage III non-small-cell lung cancer in UK clinical practice-Are the PACIFIC trial outcomes achievable in the real world? [0.03%]
在英国临床实践中III期非小细胞肺癌患者根治性同步放化疗后接受巩固免疫治疗的现状——PACIFIC研究结果可以在真实世界中实现吗？
Radwa Fawzy Ahmed,Paul Fenton,Adityanarayan Bhatnagar et al.
Radwa Fawzy Ahmed et al.
Introduction: PACIFIC trial demonstrates improved progression-free survival (PFS) and overall survival (OS) in patients with locally advanced non-small-cell lung cancer (NSCLC) treated with platinum-based concurrent chemo...
Lag3 and PD-1 pathways preferentially regulate NFAT-dependent TCR signalling programmes during early CD4+ T cell activation [0.03%]
LAG3和PD-1途径在早期活化CD4+T细胞过程中选择性调节NFAT依赖型TCR信号转导程序
Lozan Sheriff,Alastair Copland,David A J Lecky et al.
Lozan Sheriff et al.
Introduction: Lag3 and PD-1 are immune checkpoints that regulate T cell responses and are current immunotherapy targets. Yet how they function to control early stages of CD4+ T cell activation remains unclear. ...